Russell Kevin Klass bought $42k of ZOMDF
Sr Vice President, Sales at Zomedica Corp.. 1,056,064 shares at an average of $0.04, traded Aug 11, 2025, filed Aug 13, 2025.
Score components
- +15RoleOfficer
- +6Trade size$42k at market
- +6Relative to holdingsHoldings up 25%
- +8Price context74% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +122.0%, 3m +134.1%, 6m +217.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001654954-25-009503, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 11, 2025 | POpen-market purchase Common Stock, without par value | +60,723 | $0.04 | $2,429 | 4,260,753 | Aug 13, 2025 |
| Aug 12, 2025 | POpen-market purchase Common Stock, without par value | +250,000 | $0.04 | $10k | 4,510,753 | Aug 13, 2025 |
| Aug 12, 2025 | POpen-market purchase Common Stock, without par value | +745,341 | $0.04 | $30k | 5,256,094 | Aug 13, 2025 |
Related signals
Other insiders at Zomedica Corp. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | ZOMDFbuy Zomedica Corp. | Russell Kevin Klass Sr Vice President, Sales | $15k 150,000 shares | +3% | |
| 28Weak | ZOMDFbuy Zomedica Corp. | Russell Kevin Klass Sr Vice President, Sales | $12k 120,000 shares | +2% | |
| 23Weak | ZOMDFbuy Zomedica Corp. | Russell Kevin Klass Sr Vice President, Sales | $475 5,000 shares | +0% | |
| 28Weak | ZOMDFbuy Zomedica Corp. | Russell Kevin Klass Sr Vice President, Sales | $20k 253,007 shares | +5% | |
| 26Weak | ZOMDFbuy Zomedica Corp. | Russell Kevin Klass Sr Vice President of Sales | $20k 500,000 shares | +16% | |
| 31Weak | ZOMDFbuy Zomedica Corp. | Russell Kevin Klass Sr Vice President of Sales | $20k 500,000 shares | +14% | |
| 51Moderate | Zomedica Corp. | Anthony K Blair COO | $4,964 100,000 shares | +11% | |
| 46Moderate | Zomedica Corp. | Karen DeHaan-Fullerton General Counsel/Corporate Secy | $5,006 104,300 shares | - | |
| 41Moderate | Zomedica Corp. | Johnny D Powers director | $23k 500,000 shares | +17% | |
| 45Moderate | Zomedica Corp. | Scott Jordan Chief Financial Officer | $19k 300,000 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.